Cochrane Database of Systematic Reviews

The Cochrane Multiple Sclerosis and Rare Disease of the CNS achived a 2017 Impact Factor of 8.700 (10 publications cited 87 times).

The ten most cited reviews contributing to the 2017 Impact Factor were:

- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis - Times Cited: 24

- Exercise therapy for fatigue in multiple sclerosis - Times Cited: 23

- Dimethyl fumarate for multiple sclerosis - Times Cited: 9

- Telerehabilitation for persons with multiple sclerosis -  Times Cited: 9

- Memory rehabilitation for people with multiple sclerosis- Times Cited: 7

- Fingolimod for relapsing-remitting multiple sclerosis - Times Cited: 5

- Alemtuzumab for multiple sclerosis  - Times Cited: 3

- Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis - Times Cited: 3

- Teriflunomide for multiple sclerosis - Times Cited: 3

- Sodium channel blockers for neuroprotection in multiple sclerosis - Times Cited: 1